Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 01 May 2015 | By Michael Mezher
Regulators in Australia today released a discussion paper intended to solicit comments on its orphan drugs program, in light of changes in the landscape for rare diseases since the program's inception in 1997.
Orphan drugs are products intended to treat, diagnose or prevent rare diseases. Because the potential treatment populations for these drugs are small, regulators often offer incentives to encourage the development of treatments for rare conditions.
In Australia, orphan drugs are defined under Regulation 16H of the Therapeutic Goods Regulations 1990, which states:
Rare diseases are defined in the act as "a disease, or condition, likely to affect not more than 2,000 individuals in Australia at any time."
To promote the development of orphan drugs, the fees paid to the Therapeutic Goods Administration (TGA) are waived for designating, evaluating and registering qualified orphan drugs under Regulation 45(12), which states:
Under the current 2014/2015 fee schedule, this can amount to a savings of $221,400 (AUD), or roughly $173,600 (USD).
According to TGA, the agency has waived roughly $35 million (AUD) in fees since 1998, when the country made its first orphan drug designation. In total, the agency has granted orphan drug designation to 287 products, at a pace that has increased from 14 designations per year in the program’s first decade to 27 designations per year between 2008-9 and 2012-13.
Since 1997, the landscape for rare diseases has changed dramatically, and TGA has had time to reflect on the successes and challenges met by its orphan drugs program.
Despite the increase in the number of drugs granted orphan designation in recent years, it has become more difficult for a disease to be classified as "rare" in Australia. This is because the current regulations use a fixed amount of patients per year as the threshold for a disease being considered rare. While other countries, including the US, Japan and Singapore, also use a fixed number for disease prevalence, other areas such as the EU, Columbia and Ukraine factor for population fluctuation by setting the prevalence at a percentage of the population.
Additionally, the threshold for orphan designation in Australia is far lower than most other regulators, regardless of whether they use a fixed population or one that accounts for population fluctuation. TGA estimates that its current population threshold works out to approximately 0.009%, compared to 0.05% in the EU and roughly 0.06% in the US.
In the chart below, the figures demonstrate how the threshold for rare disease has changed over time in the US and Australia.
Australia
18, 532,200 ( 1997)
21,507,717 ( 2011)
23,129,300
<2,000
0.0108%, 0.0093%, 0.0086%
United States
234,721,000 ( 1983)
308,745,538 ( 2010)
316,128,839
<200,000
0.0852%, 0.0648%, 0.0633%
European Union
5 per 10,000
0.05%
TGA has also found that as treatments for rare diseases become more effective, patients with rare diseases are living longer, leading to an increase in their populations. TGA demonstrates this by looking at population estimates for patients with hemophilia A, which have increased from 1,793 to 1,954 between 2009-10 and 2012-13.
In light of the changes in the rare disease landscape, TGA is asking for input from the public on potential reforms to its orphan drugs program.
Some of the questions TGA is asking include how it should apply fees and waivers in the future, and if it should change how it defines rare diseases. The agency is also considering varying the definition of orphan drugs to accommodate for the recent trend of targeting narrow patient subsets or specific disease stages in the indication of a drug.
TGA also acknowledges that the current population threshold for orphan drug status is "considerably lower" than other regulators, and calls for suggestions on how the definition could be altered to account for population growth.
Based on the factors TGA is considering for reform, the agency is presenting four reform packages that encompass the possible combinations of answers to its questions. The agency asks that interested parties submit their input by 15 June 2015.
TGA Discussion Paper
Tags: Orphan drugs, rare disease
Regulatory Focus newsletters
All the biggest regulatory news and happenings.